Diethylene Glycol Monoethyl Ether
CAS 111-90-0
Diethylene Glycol Monoethyl Ether (CAS 111-90-0) is a pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| ETHOXYDIGLYCOL | 1311147 | SU | MTHSPL |
| DIETHYLENE GLYCOL MONOETHYL ETHER | 1311147 | SU | MTHSPL |
| Diethylene Glycol Monoethyl Ether | 1311147 | SU | MTHSPL |
| diethylene glycol monoethyl ether | 1311147 | SU | MTHSPL |
| diethylene glycol monoethyl ether | 1311147 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Diethylene Glycol Monoethyl Ether used for in pharmaceutical contexts?
Diethylene Glycol Monoethyl Ether (CAS 111-90-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Diethylene Glycol Monoethyl Ether?
No adverse-event association or SIDER side-effect rows are rendered for Diethylene Glycol Monoethyl Ether in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Diethylene Glycol Monoethyl Ether also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Ethoxydiglycol with EU status "restricted".
What clinical phase is Diethylene Glycol Monoethyl Ether in?
No phase 1-4 clinical development badge is rendered for Diethylene Glycol Monoethyl Ether because the matched compound identifier rows do not contain a max-phase value.